Invizius Information

Invizius is a spin-out based on world-class Complement research carried out at the University of Edinburgh, Scotland. Complement is 1.3b years old and part of the innate immune system. As it is the most ancient part of the immune system it is involved at the beginning of every inflammatory response. We fight inflammation at its source. Invizius is developing Second Generation Complement Therapeutics to significantly improve the clinical outcomes of patients with dysregulated complement systems leading to inflammation and fibrosis. Our first indication for H-Guard is in Acute Kidney Injury receiving CRRT where there is filter membrane associated Complement driven damage to renal tubule cells as well as local and systemic inflammatory damage. Our second product Meso-Guard is for patients on Renal replacement Therapy receiving Peritoneal Dialysis. This product should extend the PD treatment window by reducing fibrotic changes caused by peritoneal dialysis fluid. Despite significant improvements in haemodialysis membranes Complement activation by contact with a foreign surface remains a serious issue with short, medium and long term clinical implications. Other acute application of H-Guard is for coating Cardiopulmonary Bypass and ECMO filters. Other applications of our platform include IgA Nephropathy, Preeclampsia, SLE and Neuroinflammation.